An interventional study of Pulsed electromagnetic field and diclofenac tablets in Electromagnetic Field and Dysmenorrhea, sponsored by Cairo University. Completed. Open to female participants aged 17 Years to 24 Years. Per ClinicalTrials.gov, last updated 2017-09-01.
Sponsored by Cairo University · Not applicable, Interventional, and Treatment
Electromagnetic field versus diclofenac drugs on primary dysmenorrhea: Arandomized controlled trial in the Egyptian women
Background: Primary dysmenorrhea is one of the most common complaints of women and is also the most common gynecological problem worldwide. These cramps are recurrent and 90% adolescent girls and about 50% women suffer from it. Purpose of the study: to determine which is more effective in alleviating primary dysmenorrhea; pulsed electromagnetic field or diclofenac drugs. Methodology: The study was a randomized, double-blinded trial, fifty adult females participated in this study, were divided randomly into two groups equal in numbers: group (A) received pulsed electromagnetic field applied on pelvic region, 3 times per week for 3 months, 20 minutes per day and group (B) received diclofenac tablets, 50 mg only with onset of menstrual pain. All participants in both groups (A and B) were assessed pre- and post-treatment through measuring progesterone level in the blood, assessment of pain using visual analogue scale and physical as well as psychological symptoms by using menstrual symptom questionnaire.
-regular menstrual cycle 21-35 days lasting 3-7 days
Exclusion Criteria:
magnetic therapy device which generate frequency from 5-100 Hz and intensity from 1 to 60 Gauss. Group (A) received 20 min 3 times per week for three month with strength 60 gauss and frequency 50 Hz
Device: Pulsed electromagnetic field · Drug: diclofenac tablets · Diagnostic Test: Visual analogue scale · Diagnostic Test: Progesterone blood level · Diagnostic Test: Menstrual symptom questionnaire
(50 mg) few hours at the onset of menstruation for 3 months
Device: Pulsed electromagnetic field · Drug: diclofenac tablets · Diagnostic Test: Visual analogue scale · Diagnostic Test: Progesterone blood level · Diagnostic Test: Menstrual symptom questionnaire
was used to determine the pain intensity level. Pain assessed before and after treatment procedure (3 month)
Device: Pulsed electromagnetic field · Drug: diclofenac tablets · Diagnostic Test: Visual analogue scale · Diagnostic Test: Progesterone blood level · Diagnostic Test: Menstrual symptom questionnaire
Sample of blood was taken to detect the level of progesterone.
Device: Pulsed electromagnetic field · Drug: diclofenac tablets · Diagnostic Test: Visual analogue scale · Diagnostic Test: Progesterone blood level · Diagnostic Test: Menstrual symptom questionnaire
to assess symptoms of dysmenorrhea.
Device: Pulsed electromagnetic field · Drug: diclofenac tablets · Diagnostic Test: Visual analogue scale · Diagnostic Test: Progesterone blood level · Diagnostic Test: Menstrual symptom questionnaire
EASY Qs portable (by ASA, Italy)
drugs
a graphic rating scale
blood test
questionnaire
Visual analogue scale
was used to determine the pain intensity level. Pain assessed before and after treatment procedure (3 month); in both groups (A and B) by (16), it is a graphic rating scale with numerical values placed equidistantly along the line. The descriptors and numbers help the subject to place her estimate on line in which (0) mean no pain, (1) equal mild pain, (2) equal moderate pain, (3) mean severe pain and (4) mean unbearable pain.
Time frame: three months
Progesterone blood level
Sample of blood was taken to detect the level of progesterone.
Time frame: three months
Menstrual symptom questionnaire
to assess symptoms of dysmenorrhea
Time frame: three months
No study locations are listed for this record.
Plan to share: Yes — Electromagnetic field versus diclofenac drugs on primary dysmenorrhea: Arandomized controlled trial in the Egyptian women
Supporting information: Study protocol
No publications or documents are linked to this record.
This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cairo University